<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20200426</date><key>pmc.key</key><document><id>3272870</id><infon key="license">CC BY-NC-ND</infon><passage><infon key="article-id_pmc">3272870</infon><infon key="article-id_pmid">22323846</infon><infon key="article-id_publisher-id">Pacini</infon><infon key="fpage">358</infon><infon key="issue">6</infon><infon key="kwd">Pregnancy Thyroid cancer Thyroxin therapy</infon><infon key="license">This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License, which permits for noncommercial use, distribution, and reproduction in any digital medium, provided the original work is properly cited and is not altered in any way. For details, please refer to http://creativecommons.org/licenses/by-nc-nd/3.0/</infon><infon key="lpage">365</infon><infon key="name_0">surname:GIBELLI;given-names:B.</infon><infon key="name_1">surname:ZAMPERINI;given-names:P.</infon><infon key="name_2">surname:PROH;given-names:M.</infon><infon key="name_3">surname:GIUGLIANO;given-names:G.</infon><infon key="section_type">TITLE</infon><infon key="title">KEY WORDS</infon><infon key="type">front</infon><infon key="volume">31</infon><infon key="year">2011</infon><offset>0</offset><text>Management and follow-up of thyroid cancer in pregnant women</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>61</offset><text>SUMMARY</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>69</offset><text>Thyroid cancer, the most common endocrine malignancy, is often detected in young female patients. Therefore, pregnancy following thyroid cancer is not infrequent, and about 10% of thyroid cancers occurring during the reproductive years are diagnosed during pregnancy or in the early post-partum period. Differentiated thyroid cancer (DTC) in young people generally has an excellent prognosis, and disease-free survival among women with DTC diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease. However, thyroid cancer detected during pregnancy may cause anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity, as weel as pregnancy following a diagnosis of thyroid cancer obviously needs both maternal and foetal management. The main objectives in clinical monitoring of pregnant thyroid cancer patients are: 1) to reach an adequate balance of maternal calcium and thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation; 2) to maintain optimal levels of maternal thyroxin to avoid possible recurrence or spread of disease; and 3) to perform safe follow-up visits for the mother and to plan further therapy when needed. Data from a review of the literature and the authors' own experience show that in patients undergoing either suppressive or substitutive thyroxine therapy foetal thyroid growth is normal at ultrasound study, newborn thyroid status is normal, and the incidence of maternal morbidity is not influenced by the pregnancy. In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1994</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2007</offset><text>Thyroid cancer, the most common endocrine malignancy, is often detected in young patients and is more frequently diagnosed in women. The median age at diagnosis is low, below 40 years in most populations. For these reasons, differentiated thyroid cancer (DTC) is one of the most common cancers in women in the reproductive age. Hence, thyroid cancer ranks among the most common cancers during pregnancy, with a prevalence of 3.6-14 per 100,000 live births, mirroring the its incidence. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2494</offset><text>Therefore, pregnancy in thyroid cancer patients is not unusual, and about 10% of thyroid cancers occurring during reproductive years are diagnosed during pregnancy or in the early post-partum period.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2694</offset><text>Some data suggest the importance of growth factors (mainly TSH, but also HCG) in growth, progression and spread of papillary tumours. In vitro oestrogens have been shown to down-regulate the NIS (sodium iodide symporter) gene and promote the production of thyroglobulin (HTG), increasing HTG-gene expression via oestrogen receptors present in thyroid tissue, without stimulating rapid cell proliferation   . This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women, although these associations â which could indicate either a causal link or a surveillance bias â may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer. However, such a relation has not yet been confirmed.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3491</offset><text>The diagnosis of a tumour during pregnancy obviously causes anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity. However, thyroid cancer in young people has generally an excellent prognosis, and survival among women with thyroid cancer diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3889</offset><text>Pregnancy is a special situation in oncology: we need to control two patients at the same time, and both are vulnerable. In addition, each situation must be considered in development, nothing is static, mainly in the first trimester. Finally, thyroid cancer patients often undergo total thyroidectomy and thus need adequate supplementation of both calcium and thyroxine.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4260</offset><text>Thus, pregnancy following thyroid cancer needs both maternal and foetal control. The main problems are: i) to reach an adequate balance of maternal thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation, ii) to maintain maternal levels of l-thyroxin to avoid possible recurrence or spread of disease, and iii) to perform safe follow-up controls for the mother and to plan further therapy when needed.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>4710</offset><text>Physiology of pregnancy</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>4734</offset><text>Thyroid hormones and foetal development</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4774</offset><text>The first endocrine structure to appear during embryonic development is the thyroid gland. At 10-12 weeks of embryo development, follicles containing colloid become visible, and the thyroid is able to incorporate iodine into thyroid hormones. Thyroid hormones are major factors for the normal development of foetal brain, and until the end of the first trimester, when the hypothalamic-pituitary- thyroid axis becomes functional, the foetal brain is strictly dependent on local deiodination of maternal thyroxine. Thyroid hormone deficiency may cause severe neurologic disorders, resulting from defects in neuronal cell differentiation and migration, axonal and dendritic outgrowth, myelin formation and synaptogenesis   . The offspring of women with a serum-free thyroxine (fT4) concentration in the lowest decile of the reference range at 12 weeks of gestation may have significant delays in neurodevelopment. The mother is the only source of foetal thyroid hormones from conception to approximately 13 weeks of gestation, when foetal thyroid function has developed.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5843</offset><text>During pregnancy, the mother's thyroid physiology undergoes many well-defined changes, leading to an increase in thyroid volume which is often associated with higher urinary iodine excretion. It is also associated with the formation of new thyroid nodules with the histological features of nodular hyperplasia. Very early in pregnancy, the increase in oestrogen levels causes an approximate doubling in thyroxine-binding globulin (TBG) that can lead to an increases in total T4 concentration and a reduced free fraction (Table I). In healthy women, the final effect consists of a significant increase in the total thyroxine pool, mainly in the first trimester. This increment may be brought about largely by thyroid stimulation induced by human chorionic gonadotropin (HCG) through its structural affinity with thyrotropin (TSH). It can be observed that a slight increase in fT4 and a reduction in TSH occur between the 9th and 12th weeks of gestation; subsequently, HCG levels decrease and TSH reaches normal non-pregnant levels. The TSH concentration generally lies within the normal range after the 16th to 18th week    . In hypothyroid or thyroidectomized pregnant women, such physiological changes obviously cannot occur. Both during suppressive or substitutive therapy, L-T4 requirement increases very early during pregnancy, reaching a plateau after 16th to 20th weeks of gestation, with a required L-T4 dosage approximately 30 to 50% higher than that administered before pregnancy.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><offset>7333</offset><text>Increase	Decrease
HCG (TSHâlike effect)	TSH
TBG, serum total T 4 and T3, T3 and T4 pool size	
HTG	
Type III 5-deiodinase, iodine clearance, T3 and T4 degradation	
Thyroid volume	
</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>7515</offset><text>Physiological changes in thyroid function during pregnancy.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7575</offset><text>Besides the well-known association between gestational hypothyroidism and impaired intellectual and cognitive development in offspring, untreated or inadequately treated and subclinical hypothyroidism is associated with foetal loss, anaemia, gestational hypertension and preeclampsia, abruption placentae, increased risk of miscarriage, foetal growth retardation, perinatal mortality and neonatal morbidity     . Finally, for thyroid cancer patients, hypothyroidism can rise the maternal risk of recurrence.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8083</offset><text>Thus, hypothyroidism must be absolutely avoided in all pregnant woman, especially in thyroid cancer patients, and therefore correct supplementation of thyroxine is of extreme importance.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>8270</offset><text>Vitamin D requirement during pregnancy</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8309</offset><text>Thyroidectomised patients often need calcium and D vitamin supplementation, and the treatment needs frequent adjustment during the pregnancy to prevent maternal and neonatal hypocalcemia. During pregnancy vitamin D and calcium metabolism undergo significant changes to provide the calcium needed for maternal skeletal preservation and foetal skeletal formation. Increased intestinal calcium absorption seems to be the primary mechanism for obtaining extra calcium in physiological pregnancy, but frequent nausea and vomiting or sometimes diarrhea reduce the amount of calcium absorbed by the mother.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8909</offset><text>Vitamin D does not occur naturally in foods. Moreover, the usual recommendations to avoid sun exposure reduces dermal synthesis of vitamin D3 Although vitamin D is undoubtedly important for foetal bone development, we know that it plays a much wider role in health and disease prevention.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9198</offset><text>Not really a vitamin, D3 is a pro-prehormone made in the skin in response to ultraviolet-B light exposure. It is the precursor to form 25-hydroxyvitamin D3 [25(OH)D3], a prehormone, which is ultimately converted to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], one of the most potent steroid hormones known. 1,25(OH)2D may interfere with many functions beyond calcium metabolism, such as foetal &quot;imprinting&quot; that may affect neurodevelopment, immune function and chronic disease susceptibility later in life, as well as soon after birth  .</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9731</offset><text>The active metabolite of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH)2 D] increases intestinal calcium absorption and decreases renal calcium excretion, thus increasing the pool of calcium available both for mother and foetus. Vitamin D and calcium deficiency can lead to maternal anorexia with poor weight gain, and impaired bone ossification or osteopenia among newborn infant.. Neonatal hypocalcemia with seizures is not uncommon in D-vitamin deficient mothers.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10196</offset><text>Vitamin D is likely safe during pregnancy and breast feeding when taken by mouth in recommended amounts, that is 10 mcg (400 USP units) of vitamin D daily in normal pregnancy. but sometimes thyroidectomised women need more. Dosage in excess of 50 mcg (2000 units) per day are not recommended, thus the treatment of postsurgical hypoparatithyroid patient calcium supplementation may be required at dosage as high as 4 g/day together with D vitamin.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10644</offset><text>The range between therapeutic and toxic doses is narrow, and vitamin D toxicity, when it occurs, is a serious problem. The first sign is a rise in the ratio of calcium to creatinine in the urine, which precedes hypercalcemia. Hypervitaminosis D is thought to be associated with a rare infant disease with supravalvular aortic stenosis, elfin facies and mental retardation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11017</offset><text>Thus doses of D vitamin and calcium supplementation, which may differ from those recommended in normal pregnancy, need to be carefully tailored in thyroidectomised patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>11191</offset><text>Thyroid cancer and pregnancy</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11220</offset><text>Treatment and follow-up of thyroid cancer in pregnant women are the same as in non-pregnant patients except for the use of radioactive iodine. There are some differences in the management of the two most important histotypes: DTC (differentiated thyroid cancer: follicular and papillary cancer) and MTC (medullary thyroid cancer) just as for non-pregnant patients [Boxes 1-2].</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1_caption</infon><offset>11597</offset><text>Box 1.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11604</offset><text>Differentiated Thyroid Cancer (DTC) â cancer arising from follicular thyroid cells </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11690</offset><text>Mostly diagnosed in young people, DTC usually has a good prognosis with an overall 90-95% long-term disease-free survival for early stage or low risk tumours, which represent the vast majority of tumours diagnosed below 40-45 years of age. According to the current staging score, DTCs of any dimension, even with nodal invasion, for patients below 45 years of age, are classified as Stage I tumours, and usually pregnant patients are below 45 years of age.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12147</offset><text>Genetic alterations activating a common pathway of the RET-RAS-BRAF signalling cascade and other chromosomal rearrangements have been identified in most DTC. The existence of common genomic changes between DTC and anaplastic carcinoma may provide convincing proof of the multi-step carcinogenesis hypothesis in which cancer cells are produced from well-differentiated benign cells by transformation caused by accumulating damage to their genome</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12592</offset><text>Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other &quot;non-RET&quot; tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells. Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC. Both hypotheses would suggest a higher thyroid neoplasm proliferation in stimulated thyroid tissue during pregnancy or adolescence, though even in growing tissues these cancers show a very good prognosis.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13296</offset><text>The best treatment for nearly all identified malignant thyroid neoplasm is surgery. The aim of the primary treatment is an adequate excision of the primary tumour and any loco-regional extension. Considerable controversy still exists over the optimal extent of primary surgical resection. According to the extent of the disease, hemithyroidectomy or radical thyroidectomy is performed. As nodal spread is relatively common, initial surgical exploration should include careful examination of the central compartment nodes (paratracheal and tracheoesophageal) as well as dissection of clinically suspicious nodes for frozen section examination. Nodes in the jugular chains should also be carefully examined with US before surgery and, when suspicious, FNAB should be obtained. If nodal involvement is confirmed, total thyroidectomy and modified radical neck dissection are indicated.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14178</offset><text>Adjuvant therapies</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14197</offset><text>Thyroid hormones â Endocrine therapy: post-operative oral administration of supraphysiologic oral doses of levothyroxine are used assuming that the suppression of endogenous production of TSH deprives TSH-dependent DTC cells of an important growth-promoting influence and the goal for basal serum TSH should be in the 0.1 to 0.4 mIU/L range.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14541</offset><text>When radical thyroidectomy is performed, the second most frequently used post-operative adjuvant therapy for non-pregnant patients with DTC is radioactive iodine (RAI, I-131) administered to eradicate persistent neck disease or distant metastatic lesions. This adjunctive therapy is supposed to destroy occult microscopic carcinoma within the thyroid remnant by being actively trapped both by normal and pathological thyroid cells, and to facilitate follow-up because serum thyroglobulin (HTG) measurements are more reliable after the destruction of residual normal thyroid tissue.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15123</offset><text>Follow-up</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15133</offset><text>Follow-up is planned according to the stage of the disease and to the extent of the surgery performed. All patients should undergo neck ultrasound and serum assay for HTG, HTG antibodies, fT4 and TSH. For thyroidectomized high-risk, non-pregnant patients, I-131 scan is also indicated, and serum HTG measurements â performed both with thyroxine deprivation or under rTSH (recombinant human TSH) stimulation â is a useful and reliable marker of disease progression or persistence.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15617</offset><text>In our experience, the best follow-up method to detect loco-regional recurrences is, without question, neck sonography, followed by a meticulous physical examination by experienced personnel and, when indicated, ultrasound-guided FNA to confirm clinical suspicion of neck recurrence.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1_caption</infon><offset>15901</offset><text>Box 2.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15908</offset><text>Medullary Thyroid Cancer (MTC) â cancer arising from parafollicular thyroid cells </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15993</offset><text>Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern. Although uncommon, MTC is interesting because of its biochemical and genetic features and clinical association, both in autosomal-dominant inherited syndromes with incomplete penetrance (MEN IIA and IIB), and in the non-MEN forms.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>16468</offset><text>Familial cases account for about 30% of MTCs. The occurrence of MTC in both sporadic and familial forms makes the clinical approach to this tumour different from that to other thyroid tumours. First, patients with MTC should always be suspected of carrying the genetic form of the disease. Secondly, the possible presence of associated conditions, such as pheochromocytoma, should be recognized before submitting patients to thyroidectomy. Lastly, since the clinical behaviour of MTC is extremely variable, this tumour represents a true therapeutic challenge.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>17028</offset><text>MTC arises from C cells secreting calcitonin, a 32-amino acid peptide. Calcitonin is the most clinically useful biochemical marker for these tumours, and C cell hyperplasia represents a pre-cancerous stage. These neuroendocrine cells are believed to be of neural crest origin, thus having a separate lineage from the endoderm-derived follicular thyroid cells. For this reason, in addition to calcitonin-gene products, such as calcitonin CGRP (calcitonin-generelated- peptide) and C-CAP (katacalcin), MTC cells express several other biochemical markers that reflect the features of diffuse neuroendocrine system, implicated in the pathogenesis of the symptoms (flushing, diarrhoea, carcinoid syndrome or Cushing's syndrome) that may occur in patients with advanced disease. These cells can also produce prostaglandins and other neuroendocrine markers such as chromogranin A, sometimes used together with calcitonin and CEA in MTC patients during follow-up.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>17984</offset><text>When dealing with MTC, we should always bear in mind that these patients may be the index-case for one of the familial forms of the disease: presymptomatic screening of relatives of MTC patients enables early diagnosis of this malignancy. Early diagnosis rather than more extensive surgery may improve survival and reduce recurrences, mostly in the MEN IIB form of MTC, which is highly aggressive.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>18382</offset><text>Biochemical screening of familial disease consists of serum calcitonin evaluation, and genetic screening of individuals with a RET mutation may also be performed. In inherited forms, the initial germline mutation produces multiple foci of cells â the so-called C-cell hyperplasia â that are susceptible to tumour formation, and each MTC is the result of a second cell transformation in one of these susceptible clones.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>18805</offset><text>Primary MTC lesions become visible at echography as solid masses, often with calcifications. Fine needle aspiration shows a mixture of round, polyhedral and spindle-shaped cells that may seem undifferentiated, and look like a variable amount of extra-cellular amyloid.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>19074</offset><text>MTCs, like other neuroendocrine tumours, can express somatostatin receptors. Follow-up of MTC patients suspected for recurrence can therefore be performed by using the somatostatin analogue octreotide (octreoscan). The presence of somatostatin receptors provides the basis for treatment with longacting analogues of somatostatin or with Y-octreotide (DOTATOC) in some patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>19452</offset><text>MTC is somewhat more aggressive than papillary or follicular carcinoma. It locally extends into lymph nodes and into the surrounding muscles and trachea, and may invade lymphatic and blood vessels and metastasize in lungs, bones and liver. Sporadic MTC tumours are often monolateral with a single localization, while familial forms are mostly bilateral and often multifocal or diffuse. For these reasons, total thyroidectomy appears to be the appropriate approach to MTC. Central neck and upper mediastinum clearance and, in addition, mono or bilateral node dissection (depending on the extent of nodal involvement) is also advisable. The most appropriate treatment for clinical N0 tumours is still a matter of debate, but most surgeons prefer prophylactic node dissection because MTC metastasize in regional lymph nodes at a very early stage.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>20296</offset><text>Surgery is the only treatment which is considered potentially curative for metastatic or recurrent medullary carcinoma. The role of radiotherapy is controversial as MTC is generally not believed to be radio-sensitive. Therapy with long-acting somatostatin analogues has been tested in metastatic disease, with some positive benefots in most patients. Radioactive iodine is ineffective because I-131 uptake by MTC cells is negligible. No reliably effective chemotherapeutic regimen has been identified. New drugs with anti-angiogenetic, anti-tyrosine kinase and anti-VEGF effects are currently under observation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>20908</offset><text>In conclusion, there are several ways to expedite the diagnosis of MTC and to follow-up patients after surgery: biochemical markers (e.g. CEA, calcitonin, katacalcin, chromogranin-A according to tumour staining), and scanning with specific ligands such as octreotide. Furthermore, there are new therapeutic approaches under validation for advanced or recurrent disease.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>21278</offset><text>Thyroid nodules in pregnancy are often misdiagnosed because of physiological thyroid increases during pregnancy, but clinical and ultrasound findings are sufficient to suspect malignancy. Skilled examiners and good quality images with grey-scale and power Doppler US seem more reliable than other techniques in detecting and differentiating malignant and benign solid thyroid nodules, especially for small lesions. Even during pregnancy, US guided fine-needle aspiration biopsy (FNA) is the investigation of choice, thanks to its reliability and safety  .</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>21834</offset><text>Papillary thyroid cancer is the most common histological type detected in pregnant women, and in most series 90% to 95% of thyroid carcinoma diagnosed are Stage I disease, with the majority found in the first trimester of pregnancy during the first antenatal visit. The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis. Although thyroid cancer during pregnancy may have a faster growth   since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal. In fact, the rates of recurrence or the disease-free period do not differ between pregnant and non-pregnant women affected by the same disease   . Hod et al. reported a single case of accelerated tumour growth during pregnancy, but this would appear to be an exception rather than the rule.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>22866</offset><text>In a large retrospective study on 595 pregnancy-associated thyroid cancers, Yasmeen et al. detected no difference in outcome, disease-free survival and morbidity when compared to age-matched non-pregnant women. Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported. An association between thyroid cancer and parity or full-term pregnancy has been assessed in many studies without significant or conclusive results.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>23361</offset><text>During pregnancy, cellular immunity undergoes changes, as reflected by a decrease in T-cell number. Pregnancyassociated immune tolerance, designed for foetal survival, might enhance disease progression. However, according to literature data and our own experience pregnancy after thyroid cancer has been shown to have no significant effect on morbidity, disease-free period or survival time. Pregnant women with thyroid cancer have been shown to have favourable outcomes regardless of the timing of diagnosis   .</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>23874</offset><text>Guidelines for evaluation and treatment of thyroid cancer must consider the gestational age but also the patients' desires. Detecting a thyroid cancer during pregnancy should not be a reason for termination of pregnancy, and in the large majority of cases it does not require urgent surgery.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>24166</offset><text>The problem of pregnancy-associated thyroid cancer can affect three groups of patients:</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>24254</offset><text>New diagnosis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>24268</offset><text>Patients with no prior history of cancer, in whom a malignant thyroid nodule is suspected or diagnosed during pregnancy.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>24389</offset><text>For these patients, surgery could be safely performed during the mid-trimester or delayed until delivery without worsening prognosis  . Thyroidectomy during pregnancy has not been associated with adverse maternal or neonatal outcomes  . There are no indications for termination of pregnancy. When surgery is planned during pregnancy, it is important to consider both gestational age and the type of general anaesthesia. Whenever possible, the operation should be performed during the second trimester or after delivery. During the first trimester, which is the organogenesis period, general anaesthetic agents may have some teratogenic potential or may increase the risk of miscarriage. In the third trimester, surgery may induce premature labour. Physiological changes of pregnancy, such as increased heart rate and blood volume, may complicate general anaesthesia, and hypotension caused by vena cava compression of the uterus during a long period in the supine position may cause foetal hypoperfusion. Postponing surgery to at least 6-7 months after diagnosis of DTC in the first trimester does not adversely affect prognosis; on the other hand, thyroidectomy can be safely performed in the second trimester of pregnancy or after delivery. Thyroxin therapy should be started immediately after surgery because untreated hypothyroidism may expose the mother to a higher risk of disease recurrence and may have an adverse effect on cognitive function and regular growth of the offspring. Regular assessments of TSH and fT4 levels every 6/8 weeks during pregnancy and breast-feeding are required to ensure an adequate dose of levothyroxine. Follow-up may be carried out on a regular basis with ultrasound techniques and thyroglobulin assay, as in non-pregnant women. Radioiodine therapy, when needed, can be safely postponed until after breast- feeding.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>26242</offset><text>&quot;Cured&quot; patients</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>26259</offset><text>Pregnant patients with a history of previously treated DTC with no evidence of recurrent or persistent disease by imaging and by thyroglobulin measurement.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>26415</offset><text>Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy. In spite of the theoretical proliferative stimulation caused by HCG and placental growth factors, published data indicate that there is no evidence that thyroid cancer can be influenced by pregnancy. In addition, follow-up studies have shown no significant increase in risk. Usually, patients are recommended to postpone pregnancy to 6-12 months after radioiodine (I-131) treatment to avoid a potentially higher risk of miscarriage in the first few months after radioiodine therapy and to allow time enough to exclude residual disease requiring further treatment   . Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring. Virtually any person treated with any dosage of I-131 is at potential risk, but experimental evidence in animals and follow-up studies in humans has failed to reveal any statistically significant effects of I-131 on chromosomal abnormalities, congenital malformation or childhood cancers. In a large retrospective study, Dottorini et al. evaluated fertility and the long-term effects of I-131 therapy in 815 women. Among those children born from I-131 treated women, the authors found only one case of ventricular septal defect and patent ductus arteriosus   . A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy. At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome  .</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>28820</offset><text>Persistent or recurrent disease</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>28852</offset><text>Pregnant patients with the evidence of persistent disease despite therapy.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>28927</offset><text>Management of these patients and providing evidencebased advice are obviously extremely difficult tasks. Patients with active DTC can be reassured that, as mentioned above, pregnancy itself does not appear to increase disease progression, and therefore a gap in treatment during pregnancy is not contraindicated. When a simple increase in serum Htg levels is observed, further therapy is not necessary. For patients with local recurrent disease, ultrasound controls by skilled hands is of outmost importance, both to help surgeons in selecting tissues for excision and to perform local therapy, such as alcoholization of small lesions. For patients with advanced disease, ultrasound control of tissue growth can help in therapeutic decisions, such as timing of surgery. Whenever possible, surgery should be carried out during the second trimester or after delivery, as for newly diagnosed thyroid cancer.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>29832</offset><text>For any patient, both with first diagnosis or recurrent disease, post-operative therapy for DTC is based on the administration of supraphysiologic &quot;suppressive&quot; oral doses of levothyroxine. This treatment has been widely used for more than 40 years, with the assumption that suppression of endogenous TSH deprives TSH-dependent DTC cells of the most important growth factor. Therefore, thyroxine therapy aims at suppressing pituitary secretion of TSH, as indicated by serum TSH levels below 0.05 mIU/L. In univariate analyses, thyroxine therapy apparently helps decrease cancer-related death rates among patients with PTC. Many series have reported reduced rates of tumour recurrence both in PTC and in FTC. Doses of L-thyroxine greater than 150/200 Î¼g (at least 2 Î¼g/kg/day) are usually needed to maintain maternal serum-free thyroxin concentrations within the upper third of the reference range and to suppress TSH levels. Usually the dosage needs to be increased as early as during the fifth week of gestation, and fT4 TSH monitoring is recommended every 6 weeks for adequate adjustment of dosage. After delivery, thyroxine dose can be gradually reduced to pre-pregnancy levels, while TSH levels should be constantly monitored  .</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>31067</offset><text>Patients with MTC whose tumours deriving from C cells are not TSH-dependent do not require suppressive therapy, but only thyroxine replacement therapy after surgery, and the dosages are the same as those used for hypothyroidism.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>31296</offset><text>Pregnancy status requires much more accuracy in assessing levothyroxine dosage to protect the foetus from maternal hypothyroidism because, as mentioned above, the mother is the only source of thyroid hormones for the embryo in the first trimester of pregnancy. With regards to pharmacokinetics, oral dosing produces therapeutic effects within 3-5 days. Approximately 40-80% of the oral dose is absorbed, with peak serum levels measured within 2-4 hour, and the half-life of the administered dose is approximately 1 week. The extent of absorption is increased in fasting status and decreased if there is inadequate intestinal absorption, often caused by other drugs, such as ferrous sulphate. Therefore, during pregnancy, thyroxin and ferrous sulphate doses should be spaced by at least 4 hours. There is limited but still important placental transfer of maternal T4 to the foetus, while placental type III deiodinase catalyzes the conversion of T4 to the more active form reverse-T3, which crosses the placental barrier, and to the less active 3,3'-diiodothyronine (T2), representing a homeostatic mechanism for maintaining T3 production in the placenta when maternal serum T4 concentrations are modified.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>32502</offset><text>Frequent monitoring and adjustment of L-T4 dosages are very important because of large fluctuations of T4 metabolism during pregnancy; calcium and D vitamin supplementation, often indispensable, must be carefully tailored  .</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>32727</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>32739</offset><text>When treating thyroid cancer in pregnancy, 3 factors should be considered:</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>32814</offset><text>The effect of cancer on pregnancy: No metastasis to placenta or foetus â no IUGR. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>32899</offset><text>Pregnancy does not seem to be compromised by thyroid cancer.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>32960</offset><text>The effect of pregnancy on cancer: In vitro accelerated cell growth, no effect seen in vivo.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>33053</offset><text> Survival and disease-free intervals identical in pregnant and non-pregnant women</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>33135</offset><text>The effects of management modalities on pregnancy outcome: No I-131, tailored therapy.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>33222</offset><text> Critical monthly adjustment of levothyroxine therapy: maintain fT4 in the upper third of reference range.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>33329</offset><text>References</text></passage><passage><infon key="fpage">76</infon><infon key="lpage">81</infon><infon key="name_0">surname:Bradley;given-names:PJ</infon><infon key="name_1">surname:Raghavan;given-names:U</infon><infon key="pub-id_pmid">15167041</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Otolaryngol Head Neck
Surg</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2004</infon><offset>33340</offset><text>Cancers presenting in the head and neck during pregnancy</text></passage><passage><infon key="fpage">15</infon><infon key="lpage">20</infon><infon key="name_0">surname:Yasmeen;given-names:S</infon><infon key="name_1">surname:Cress;given-names:R</infon><infon key="name_2">surname:Romano;given-names:PS</infon><infon key="section_type">REF</infon><infon key="source">Int J Gynecol Obstet</infon><infon key="type">ref</infon><infon key="volume">2005</infon><infon key="year">2005</infon><offset>33397</offset><text>Thyroid cancer in pregnancy</text></passage><passage><infon key="fpage">667</infon><infon key="lpage">670</infon><infon key="name_0">surname:Hay;given-names:I</infon><infon key="pub-id_pmid">10447012</infon><infon key="section_type">REF</infon><infon key="source">Thyroid</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1999</infon><offset>33425</offset><text>Nodular thyroid disease diagnosed during pregnancy: how and when to treat</text></passage><passage><infon key="fpage">127</infon><infon key="lpage">128</infon><infon key="name_0">surname:O'Connell;given-names:TB</infon><infon key="name_1">surname:O'Doherty;given-names:MJ</infon><infon key="pub-id_pmid">10758605</infon><infon key="section_type">REF</infon><infon key="source">Nucl Med Commun</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2000</infon><offset>33499</offset><text>Differentiated thyroid cancer and pregnancy</text></passage><passage><infon key="fpage">5705</infon><infon key="lpage">5711</infon><infon key="name_0">surname:Furlanetto;given-names:TW</infon><infon key="name_1">surname:Nguyen;given-names:LQ</infon><infon key="name_2">surname:Jameson;given-names:JL</infon><infon key="pub-id_pmid">10579335</infon><infon key="section_type">REF</infon><infon key="source">Endocrinology</infon><infon key="type">ref</infon><infon key="volume">140</infon><infon key="year">1999</infon><offset>33543</offset><text>Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells</text></passage><passage><infon key="fpage">1056</infon><infon key="lpage">1065</infon><infon key="name_0">surname:Truong;given-names:T</infon><infon key="name_1">surname:Orsi;given-names:L</infon><infon key="name_2">surname:Dubourdieu;given-names:D</infon><infon key="pub-id_pmid">15901626</infon><infon key="section_type">REF</infon><infon key="source">Am J Epidemiol</infon><infon key="type">ref</infon><infon key="volume">161</infon><infon key="year">2005</infon><offset>33645</offset><text>Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">8</infon><infon key="name_0">surname:Patel;given-names:J</infon><infon key="name_1">surname:Landers;given-names:K</infon><infon key="name_2">surname:Li;given-names:H</infon><infon key="pub-id_pmid">21212091</infon><infon key="section_type">REF</infon><infon key="source">J Endocrinol</infon><infon key="type">ref</infon><infon key="volume">209</infon><infon key="year">2011</infon><offset>33820</offset><text>Thyroid hormones and fetal neurological development</text></passage><passage><infon key="fpage">282</infon><infon key="lpage">288</infon><infon key="name_0">surname:Pop;given-names:VJ</infon><infon key="name_1">surname:Brouwers;given-names:EP</infon><infon key="name_2">surname:Vader;given-names:HL</infon><infon key="pub-id_pmid">12919150</infon><infon key="section_type">REF</infon><infon key="source">Clin Endocrinol (Oxf)</infon><infon key="type">ref</infon><infon key="volume">59</infon><infon key="year">2003</infon><offset>33872</offset><text>Maternal Hypothyroxinaemia during early pregnancy and subsequnt child development: a 3-year follow-up study</text></passage><passage><infon key="fpage">3975</infon><infon key="lpage">3987</infon><infon key="name_0">surname:Morreale de Escobar;given-names:G</infon><infon key="name_1">surname:Obregon;given-names:MJ</infon><infon key="name_2">surname:Escobar dle Rey;given-names:F</infon><infon key="pub-id_pmid">11095417</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol
Metab</infon><infon key="type">ref</infon><infon key="volume">85</infon><infon key="year">2000</infon><offset>33980</offset><text>Is neuropsychological developement related to maternal hypothyroidism or to maternal hypothyroxinemia?</text></passage><passage><infon key="fpage">S45</infon><infon key="issue">(Suppl A)</infon><infon key="lpage">S54</infon><infon key="name_0">surname:Glinoer;given-names:D</infon><infon key="pub-id_pmid">12914727</infon><infon key="section_type">REF</infon><infon key="source">Growth Horm IGF Res</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2003</infon><offset>34083</offset><text>Management of hypo- and hyperthyroidism durino pregnancy</text></passage><passage><infon key="fpage">233</infon><infon key="lpage">245</infon><infon key="name_0">surname:Shah;given-names:MS</infon><infon key="name_1">surname:Davies;given-names:TF</infon><infon key="name_2">surname:Stagnaro-Green;given-names:A</infon><infon key="pub-id_pmid">14605605</infon><infon key="section_type">REF</infon><infon key="source">Minerva Endocrinol</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2003</infon><offset>34140</offset><text>The thyroid during pregnancy: a physiological and pathological stress test</text></passage><passage><infon key="fpage">241</infon><infon key="lpage">249</infon><infon key="name_0">surname:Alexander;given-names:EK</infon><infon key="name_1">surname:Marqusee;given-names:E</infon><infon key="name_2">surname:Lawrence;given-names:J</infon><infon key="pub-id_pmid">15254282</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">351</infon><infon key="year">2004</infon><offset>34215</offset><text>Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism</text></passage><passage><infon key="fpage">549</infon><infon key="lpage">555</infon><infon key="name_0">surname:Haddow;given-names:JE</infon><infon key="name_1">surname:Palomaki;given-names:GE</infon><infon key="name_2">surname:Allan;given-names:WC</infon><infon key="pub-id_pmid">10451459</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">341</infon><infon key="year">1999</infon><offset>34325</offset><text>Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child</text></passage><passage><infon key="fpage">31</infon><infon key="lpage">41</infon><infon key="name_0">surname:Lazarus;given-names:JH</infon><infon key="pub-id_pmid">15649099</infon><infon key="section_type">REF</infon><infon key="source">Treat Endocrinol</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2005</infon><offset>34429</offset><text>Thyroid disorders associated with pregnancy etiology, diagnosis and management</text></passage><passage><infon key="fpage">123</infon><infon key="lpage">127</infon><infon key="name_0">surname:Lao;given-names:TT</infon><infon key="pub-id_pmid">15758602</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Obstet
Gynecol</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2005</infon><offset>34508</offset><text>Thyroid disorders in pregnangy</text></passage><passage><infon key="fpage">49</infon><infon key="lpage">73</infon><infon key="name_0">surname:Obregon;given-names:MJ</infon><infon key="name_1">surname:Calvo;given-names:RM</infon><infon key="name_2">surname:Escobar del Rey;given-names:F</infon><infon key="name_3">surname:Pinchera;given-names:A</infon><infon key="name_4">surname:Mann;given-names:K</infon><infon key="name_5">surname:Hostalec;given-names:U</infon><infon key="section_type">REF</infon><infon key="source">The thyroid and age</infon><infon key="type">ref</infon><infon key="year">1998</infon><offset>34539</offset><text>Thyroid hormones and fetal developmernt</text></passage><passage><infon key="fpage">1068</infon><infon key="lpage">1108</infon><infon key="name_0">surname:Glinoer;given-names:D</infon><infon key="name_1">surname:Braverman;given-names:LE</infon><infon key="name_2">surname:Utiger;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">Werner &amp; Ingbar's The Thyroid: a fundamental and clinical text</infon><infon key="type">ref</infon><infon key="year">2005</infon><offset>34579</offset></passage><passage><infon key="fpage">1072</infon><infon key="lpage">1078</infon><infon key="name_0">surname:Burrow;given-names:GN</infon><infon key="name_1">surname:Fisher;given-names:DA</infon><infon key="name_2">surname:Larsen;given-names:PR</infon><infon key="pub-id_pmid">8090169</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">331</infon><infon key="year">1994</infon><offset>34580</offset><text>Maternal and fetal thyroid function</text></passage><passage><infon key="fpage">893</infon><infon key="lpage">905</infon><infon key="name_0">surname:Neale;given-names:D</infon><infon key="name_1">surname:Burrow;given-names:G</infon><infon key="section_type">REF</infon><infon key="source">Obstet
Gynecol Clin N Am</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2004</infon><offset>34616</offset><text>Thyroid disease in pregnancy</text></passage><passage><infon key="fpage">8</infon><infon key="lpage">26</infon><infon key="name_0">surname:Santisteban;given-names:P</infon><infon key="name_1">surname:Braverman;given-names:LE</infon><infon key="name_2">surname:Utiger;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">Werner &amp; Ingbar's The Thyroid: a fundamental and clinical text</infon><infon key="type">ref</infon><infon key="year">2005</infon><offset>34645</offset><text>Development and anatomy of the hypothalamic- pituitary-thyroid axis</text></passage><passage><infon key="fpage">232</infon><infon key="lpage">241</infon><infon key="name_0">surname:Blazer;given-names:S</infon><infon key="name_1">surname:Moreh-Waterman;given-names:Y</infon><infon key="name_2">surname:Miller-Lotan;given-names:R</infon><infon key="pub-id_pmid">12907094</infon><infon key="section_type">REF</infon><infon key="source">Obstet Gynecol</infon><infon key="type">ref</infon><infon key="volume">102</infon><infon key="year">2003</infon><offset>34713</offset><text>Maternal hypothyroidism may affect fetal growth and neonatal thyroid function</text></passage><passage><infon key="fpage">1063</infon><infon key="lpage">1070</infon><infon key="name_0">surname:Krassas;given-names:GE</infon><infon key="pub-id_pmid">11119728</infon><infon key="section_type">REF</infon><infon key="source">Fertil
Steril</infon><infon key="type">ref</infon><infon key="volume">74</infon><infon key="year">2000</infon><offset>34791</offset><text>Thyroid disease and female reproduction</text></passage><passage><infon key="fpage">1740</infon><infon key="issue">(Suppl)</infon><infon key="lpage">1747</infon><infon key="name_0">surname:Speker;given-names:B</infon><infon key="section_type">REF</infon><infon key="source">Am J Clin
Nutr</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">Am J Clin
Nutr</infon><offset>34831</offset><text>Vit D requirement during pregnancy</text></passage><passage><infon key="fpage">1287</infon><infon key="lpage">1290</infon><infon key="name_0">surname:Hollis;given-names:BW</infon><infon key="name_1">surname:Wagner;given-names:CL</infon><infon key="pub-id_pmid">16636329</infon><infon key="section_type">REF</infon><infon key="source">CMAJ</infon><infon key="type">ref</infon><infon key="volume">174</infon><infon key="year">2006</infon><offset>34866</offset><text>Nutritional vitamin D status during pregnancy: reasons for concern</text></passage><passage><infon key="fpage">367</infon><infon key="lpage">371</infon><infon key="name_0">surname:McGrath;given-names:J</infon><infon key="pub-id_pmid">11359362</infon><infon key="section_type">REF</infon><infon key="source">Med Hypotheses</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2001</infon><offset>34933</offset><text>Does &quot;imprinting&quot; with low prenatal vitamin D contribute to the risk of various adult disorders?</text></passage><passage><infon key="fpage">117</infon><infon key="lpage">136</infon><infon key="name_0">surname:LeBeau;given-names:SO</infon><infon key="name_1">surname:Mandel;given-names:SJ</infon><infon key="pub-id_pmid">16310645</infon><infon key="section_type">REF</infon><infon key="source">Endocrinol metab Clin North Am</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">2006</infon><offset>35030</offset><text>Thyroid disorder during pregnancy</text></passage><passage><infon key="fpage">81</infon><infon key="lpage">89</infon><infon key="name_0">surname:Rosen;given-names:IB</infon><infon key="name_1">surname:Korman;given-names:M</infon><infon key="name_2">surname:Walfish;given-names:PG</infon><infon key="pub-id_pmid">9103951</infon><infon key="section_type">REF</infon><infon key="source">Clin Obstet
Gynecol</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">1997</infon><offset>35064</offset><text>Thyroid nodular disease in pregnancy: current diagnosis and treatment</text></passage><passage><infon key="fpage">61</infon><infon key="lpage">64</infon><infon key="name_0">surname:Kobayashi;given-names:K</infon><infon key="name_1">surname:Tanaka;given-names:Y</infon><infon key="name_2">surname:Ishiguro;given-names:S</infon><infon key="pub-id_pmid">8289456</infon><infon key="section_type">REF</infon><infon key="source">J Surg Oncol</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">1994</infon><offset>35134</offset><text>Rapidly growing thyroid carcinoma during pregnancy</text></passage><passage><infon key="fpage">774</infon><infon key="lpage">779</infon><infon key="name_0">surname:Hod;given-names:M</infon><infon key="name_1">surname:Sharony;given-names:R</infon><infon key="name_2">surname:Friedman;given-names:S</infon><infon key="pub-id_pmid">2677860</infon><infon key="section_type">REF</infon><infon key="source">Obstet
Gynecol Surv</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">1989</infon><offset>35185</offset><text>Pregnancy and thyroid carcinoma: A review of incidence, course and prognosis</text></passage><passage><infon key="fpage">433</infon><infon key="lpage">435</infon><infon key="name_0">surname:Chloe;given-names:W</infon><infon key="name_1">surname:Mc Dougall;given-names:IR</infon><infon key="pub-id_pmid">7711507</infon><infon key="section_type">REF</infon><infon key="source">Thyroid</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">1994</infon><offset>35262</offset><text>Thyroid cancer in pregnant women: diagnostic and therapeutic management</text></passage><passage><infon key="fpage">41</infon><infon key="lpage">71</infon><infon key="name_0">surname:Mestman;given-names:JH</infon><infon key="name_1">surname:Goodwin;given-names:M</infon><infon key="name_2">surname:Montoro;given-names:MM</infon><infon key="pub-id_pmid">7781627</infon><infon key="section_type">REF</infon><infon key="source">Endocrinol Metab Clin North Am</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1995</infon><offset>35334</offset><text>Thyroid disorders of pregnancy</text></passage><passage><infon key="fpage">339</infon><infon key="lpage">344</infon><infon key="name_0">surname:Zamperini;given-names:P</infon><infon key="name_1">surname:Gibelli;given-names:B</infon><infon key="name_2">surname:Gilardi;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">ACTA Otorhinolarynngol
Ital</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2009</infon><offset>35365</offset><text>Pregnancy and thyroid cancer: ultrasound study of foetal thyroid</text></passage><passage><infon key="fpage">2862</infon><infon key="lpage">2866</infon><infon key="name_0">surname:Moosa;given-names:M</infon><infon key="name_1">surname:Mazzaferri;given-names:EL</infon><infon key="pub-id_pmid">9284711</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">1997</infon><offset>35430</offset><text>Outcome of differentiated thyroid cancer diagnosed in pregnant women</text></passage><passage><infon key="fpage">2317</infon><infon key="lpage">2320</infon><infon key="name_0">surname:Tan;given-names:GH</infon><infon key="name_1">surname:Gharib;given-names:H</infon><infon key="name_2">surname:Goellner;given-names:JR</infon><infon key="pub-id_pmid">8911238</infon><infon key="section_type">REF</infon><infon key="source">Arch Intern Med</infon><infon key="type">ref</infon><infon key="volume">156</infon><infon key="year">1996</infon><offset>35499</offset><text>Management of thyroid nodules in pregnancy</text></passage><passage><infon key="fpage">161</infon><infon key="lpage">177</infon><infon key="name_0">surname:Hamer;given-names:CL</infon><infon key="name_1">surname:McCready;given-names:VR</infon><infon key="pub-id_pmid">8841389</infon><infon key="section_type">REF</infon><infon key="source">Cancer Treat Rev</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">1996</infon><offset>35542</offset><text>Thyroid cancer: differentiated carcinoma</text></passage><passage><infon key="fpage">404</infon><infon key="lpage">406</infon><infon key="name_0">surname:Vini;given-names:L</infon><infon key="name_1">surname:Hyer;given-names:S</infon><infon key="name_2">surname:Pratt;given-names:B</infon><infon key="pub-id_pmid">10229904</infon><infon key="section_type">REF</infon><infon key="source">Eur J Endocrinol</infon><infon key="type">ref</infon><infon key="volume">140</infon><infon key="year">1999</infon><offset>35583</offset><text>Management of differentiated thyroid cancer diagnosed during pregnancy</text></passage><passage><infon key="fpage">199</infon><infon key="lpage">203</infon><infon key="name_0">surname:Nam;given-names:KH</infon><infon key="name_1">surname:Yoon;given-names:JH</infon><infon key="name_2">surname:Chang;given-names:HS</infon><infon key="pub-id_pmid">16118775</infon><infon key="section_type">REF</infon><infon key="source">J Surg Oncol</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">2005</infon><offset>35654</offset><text>Optimal timing of surgery in well-differentiated thyroid carcinoma detected during pregnancy</text></passage><passage><infon key="fpage">612</infon><infon key="lpage">615</infon><infon key="name_0">surname:Schlumberger;given-names:M</infon><infon key="name_1">surname:De Vathaire;given-names:F</infon><infon key="name_2">surname:Ceccarelli;given-names:C</infon><infon key="pub-id_pmid">8691250</infon><infon key="section_type">REF</infon><infon key="source">J Nucl Med</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">1996</infon><offset>35747</offset><text>Parmentier C Exposure to radioactive iodine-131 scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients</text></passage><passage><infon key="fpage">449</infon><infon key="lpage">455</infon><infon key="name_0">surname:Bal;given-names:C</infon><infon key="name_1">surname:Kumar;given-names:A</infon><infon key="name_2">surname:Tripathi;given-names:M</infon><infon key="pub-id_pmid">16095849</infon><infon key="section_type">REF</infon><infon key="source">Int J Radiat Oncol Biol Phys</infon><infon key="type">ref</infon><infon key="volume">63</infon><infon key="year">2005</infon><offset>35874</offset><text>High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring</text></passage><passage><infon key="fpage">21</infon><infon key="lpage">27</infon><infon key="name_0">surname:Dottorini;given-names:ME</infon><infon key="name_1">surname:Lomuscio;given-names:G</infon><infon key="name_2">surname:Mazzucchelli;given-names:L</infon><infon key="pub-id_pmid">7799075</infon><infon key="section_type">REF</infon><infon key="source">J Nucl Med</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">1995</infon><offset>36030</offset><text>Assessment of female fertility and carcinogenesis after I-131 therapy for differntiated thyroid cancer</text></passage><passage><infon key="fpage">432</infon><infon key="lpage">438</infon><infon key="name_0">surname:Takano;given-names:T</infon><infon key="name_1">surname:Amino;given-names:N</infon><infon key="pub-id_pmid">15929664</infon><infon key="section_type">REF</infon><infon key="source">Thyroid</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2005</infon><offset>36133</offset><text>Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma</text></passage><passage><infon key="fpage">537</infon><infon key="lpage">544</infon><infon key="name_0">surname:Thomas;given-names:T</infon><infon key="name_1">surname:Nowka;given-names:K</infon><infon key="name_2">surname:Lan;given-names:L</infon><infon key="pub-id_pmid">16839255</infon><infon key="section_type">REF</infon><infon key="source">Thyroid</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2006</infon><offset>36223</offset><text>Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid glands</text></passage><passage><infon key="fpage">485</infon><infon key="lpage">489</infon><infon key="name_0">surname:Zhang;given-names:P</infon><infon key="name_1">surname:Zuo;given-names:H</infon><infon key="name_2">surname:Ozaki;given-names:T</infon><infon key="pub-id_pmid">16930327</infon><infon key="section_type">REF</infon><infon key="source">Pathol Int</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2006</infon><offset>36335</offset><text>Cancer stem cell hypothesis in thyroid cancer</text></passage><passage><infon key="fpage">290</infon><infon key="lpage">295</infon><infon key="name_0">surname:Gibelli;given-names:B</infon><infon key="name_1">surname:El-Fattah;given-names:A</infon><infon key="name_2">surname:Giugliano;given-names:G</infon><infon key="pub-id_pmid">20463832</infon><infon key="section_type">REF</infon><infon key="source">Acta Otorhinolaryngol Ital</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2009</infon><offset>36381</offset><text>Thyroid stem cells - danger or resource?</text></passage><passage><infon key="fpage">292</infon><infon key="lpage">306</infon><infon key="name_0">surname:Kondo;given-names:T</infon><infon key="name_1">surname:Ezzat;given-names:S</infon><infon key="name_2">surname:Asa;given-names:S.L.</infon><infon key="pub-id_pmid">16557281</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Cancer</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2006</infon><offset>36422</offset><text>Pathogenic mechanism in thyroid follicular-cell neoplasia</text></passage><passage><infon key="fpage">967</infon><infon key="lpage">989</infon><infon key="name_0">surname:Gagel;given-names:RF</infon><infon key="name_1">surname:Hoff;given-names:A</infon><infon key="name_2">surname:O, Cote;given-names:GJ</infon><infon key="name_3">surname:Braverman;given-names:LE</infon><infon key="name_4">surname:Utiger;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">Werner &amp; Ingbar's The Thyroid: a fundamental and clinical text</infon><infon key="type">ref</infon><infon key="year">2005</infon><offset>36480</offset><text>Medullary thyroid carcinoma</text></passage><passage><infon key="fpage">967</infon><infon key="lpage">989</infon><infon key="name_0">surname:Gimm;given-names:O</infon><infon key="name_1">surname:Dralle;given-names:H</infon><infon key="name_2">surname:Biersack;given-names:HJ</infon><infon key="name_3">surname:Grunwald;given-names:F</infon><infon key="section_type">REF</infon><infon key="source">Werner &amp; Ingbar's The Thyroid: a fundamental and clinical text</infon><infon key="type">ref</infon><infon key="year">2005</infon><offset>36508</offset><text>Therapy for medullary thyroid cancer</text></passage><passage><infon key="fpage">297</infon><infon key="lpage">310</infon><infon key="name_0">surname:Raue;given-names:F</infon><infon key="name_1">surname:Raue;given-names:FK</infon><infon key="name_2">surname:Biersack;given-names:HJ</infon><infon key="name_3">surname:Grunwald;given-names:F</infon><infon key="section_type">REF</infon><infon key="source">Thyroid Cancer</infon><infon key="type">ref</infon><infon key="year">2005</infon><offset>36545</offset><text>Diagnosis of medullary thyroid cancer</text></passage></document></collection>
